Author/Authors :
Rossom, Rebecca C. HealthPartners Institute, Minneapolis, MN USA , Sperl-Hillen, JoAnn M. HealthPartners Institute, Minneapolis, MN USA , O’Connor, Patrick J. HealthPartners Institute, Minneapolis, MN USA , Crain, A. Lauren HealthPartners Institute, Minneapolis, MN USA , Nightingale, Laurel HealthPartners Institute, Minneapolis, MN USA , Pylkas, Anne HealthPartners Medical Group, Minneapolis, MN USA , Huntley, Kristen V. Center for the Clinical Trials Network - National Institute on Drug Abuse, Bethesda, MA USA , Bart, Gavin University of Minnesota School of Medicine, Minneapolis, MN USA
Abstract :
Objective
Most Americans with opioid use disorder (OUD) do not receive indicated medical care. A clinical decision support (CDS) tool for primary care providers (PCPs) could address this treatment gap. Our primary objective was to build OUD-CDS tool and demonstrate its functionality and accuracy. Secondary objectives were to achieve high use and approval rates and improve PCP confidence in diagnosing and treating OUD.
Methods
A convenience sample of 55 PCPs participated. Buprenorphine-waivered PCPs (n = 8) were assigned to the intervention. Non-waivered PCPs (n = 47) were randomized to intervention (n = 24) or control (n = 23). Intervention PCPs received access to the OUD-CDS, which alerted them to patients at potentially increased risk for OUD or overdose and guided diagnosis and treatment. Control PCPs provided care as usual.
Results
The OUD-CDS was functional and accurate following extensive multi-phased testing. PCPs used the OUD-CDS in 5% of encounters with at-risk patients, far less than the goal of 60%. OUD screening confidence increased for all intervention PCPs and OUD diagnosis increased for non-waivered intervention PCPs. Most PCPs (65%) would recommend the OUD-CDS and found it helpful with screening for OUD and discussing and prescribing OUD medications.
Discussion
PCPs generally liked the OUD-CDS, but use rates were low, suggesting the need to modify CDS design, implementation strategies and integration with existing primary care workflows.
Conclusion
The OUD-CDS tool was functional and accurate, but PCP use rates were low. Despite low use, the OUD-CDS improved confidence in OUD screening, diagnosis and use of buprenorphine.
NIH Trial registration NCT03559179. Date of registration: 06/18/2018. URL: https://clinicaltrials.gov/ct2/show/NCT03559179
Supplementary Information
The online version contains supplementary material available at 10.1186/s13722-021-00245-7.